CELL LINES
Contributor Information
- Name Anne-Marie Mes-Masson and Diane Provencher
- Institute Centre Hospitalier de Luniversité de Montréal
- Primary citation Fleury et al. 2015. Genes & Cancer. 6(9-10):378-398. PMID: 26622941
Tool Details
- Tool name: OV-4485 cell line
- Alternate names: OV-4485
- Tool type: Cell Lines
- Organism: Human
- Donor: Age of diagnosis: 55; BRCA hereditary status: BRCA1(+); Grade 2 Stage IIIC; Mutations: TP53, BRCA1; Carboplatin/Taxol/maintenance Sorafenib vs Placebo trial
- Tissue: Derived from ascites
- Gender: Female
- Cancer type: Gynaecologic cancer
- Morphology: Formed loosely compact spheroids with irregular margins
- Growth properties: Adherent
- CRISPR: No
- Receptors of note: No
- Description: Epithelial ovarian cancer cell lines spontaneously derived from high-grade serious ascites. Patient harbored BRCA1:IVS14-1G>T mutation
- Research area: Cancer
- Production details: Established from the cellular fraction of ascites collected by centrifugation. The cell lines were then maintained for 40 days in OSE with medium replaced weekly.
- Additional notes: Patient 4485 was age 55 at diagnosis, BRCA hereditary status was BRCA1(+), and no prior personal history of cancer. Patient received Carboplatin/taxol, interval sugery, and was later in a clinical trial: maintenance sorafenib vs placebo trial.
- For Research Use Only
Target Details
Application Details
Handling
- Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
- Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
- Cultured in antibiotics?: Amphotericin B and Gentamicin
Documentation
Related Tools
References
- • Vias et al. 2023. Elife. 11
- • 12:e83867. PMID: 37166279 Sevinyan et al. 2022. Cancers (Basel). 16
- • 14(22):5628. PMID: 36428724 Asare-Werehene et al. 2023. Cancers (Basel). 30
- • 15(9):2566. PMID: 37174032
.svg)
.svg)
